“We’re taking a pharmaceutical approach to nature,” says Joel Stanley, Ajna BioSciences’ 45-year-old CEO and founder. “Our entire process is totally organic, which means we could produce the first USDA-certified organic pharmaceutical.” https://t.co/9US1Ftcs8z ...

The biotech veteran was involved in the development of several approved drugs, likely making him a reassuring choice for a pharmaceutical industry that’s facing pressure from the Trump administration to lower prices and move drug manufacturing to the US https://t.co/ZnLX4JBobH ...

Weed Rx: “Pharmaceutical cannabis is the biggest future for cannabis,” says Joel Stanley (left, with his brother Jared), founder of Ajna BioSciences, which has a botanical drug in the FDA pipeline. https://t.co/X1ri3kksyx https://t.co/X1ri3kksyx ...

Financial Performance - Telescope Innovations Corp. reported revenues of CAD 1.4 million for the fiscal quarter ended May 31, 2025, compared to CAD 1.2 million for the same quarter in FY 2024, reflecting a growth of approximately 14% [1][7] - The company incurred an adjusted EBITA loss of CAD 0.1 million, which is an increase from a loss of CAD 0.05 million in the comparable quarter of FY 2024 [1][7] - Total expenses for the quarter were CAD 1.9 million, up from CAD 1.4 million in the same quarter of FY 2024 [7] Operational Highlights - Telescope shipped its first battery-grade lithium sulfide (Li₂S) samples to major battery industry groups in Asia and North America, marking the initial customer evaluation of its proprietary low-temperature production process [4] - The company is part of the Arkansas Lithium Technology Accelerator, focusing on innovating the battery supply chain [4] - The DirectInject-LC™ product experienced significant growth, with sales and order pipelines more than doubling compared to Q3 2024 [7] Strategic Partnerships - Telescope is collaborating with Pfizer to develop a "Phase 1" Self-Driving Lab (SDL) platform, which aims to enhance chemistry research efficiency by up to 100 times compared to traditional methods [7] - The company is working with Mettler Toledo on a global distribution campaign, executing 11 application feasibility studies and participating in lead-generating events [7] Company Overview - Telescope Innovations Corp. focuses on developing scalable manufacturing processes and tools for the pharmaceutical and chemical industries, utilizing advanced technologies such as robotic platforms and artificial intelligence [6]

Weed Rx: “Pharmaceutical cannabis is the biggest future for cannabis,” says Joel Stanley (left, with his brother Jared), founder of Ajna BioSciences, which has a botanical drug in the FDA pipeline. https://t.co/Q2rTHfUQwO https://t.co/Q2rTHfUQwO ...

Industry Focus - Pharmaceutical cannabis is considered the biggest future for cannabis industry [1] - Ajna BioSciences, founded by Joel Stanley, has a botanical drug in the FDA pipeline [1] Company Information - Joel Stanley (with his brother Jared) is the founder of Ajna BioSciences [1] - Charlotte's Web provided the photo [1]

Group 1 - The article highlights significant announcements in the stock market from Sunday to Thursday, including "suspensions and resumption of trading, shareholding changes, investment wins, acquisitions, earnings reports, unlocks, and high transfers" [1] - Important announcements are marked in red to assist investors in identifying investment hotspots and preventing various black swan events, providing ample time for analysis and selection of suitable listed companies [1] - The article mentions a company that has achieved the supply of solid-state battery cathode materials in hundred-kilogram samples [1] Group 2 - Another company is noted for its services provided to certain military research institutes, integrating cloud computing, military industry, blockchain, robotics, AI, Huawei Harmony, and state-owned cloud [1] - A company in the innovative drug sector, particularly in weight loss drugs, is projected to have a net profit increase of over three times year-on-year in the first half of the year [1]

Innovation & R&D - The US leads the world in life science innovation due to a combination of factors including investment in basic research, venture capital, strong companies, and protection of intellectual property [3][5] - Big Pharma increasingly relies on external innovation, with internal drug development accounting for less than 30% of FDA approvals between 2015 and 2021 [11] - AI and machine learning are accelerating drug discovery by enabling the screening of 1.7 million compounds in approximately 5-10 days, significantly reducing the time required for identifying lead compounds [3][14][15] Investment & Finance - In 2021, the pharmaceutical industry invested over $80 billion annually in R&D, a tenfold increase over 10 years, representing approximately 25% of pharma companies' revenues [4] - Venture capital firms investing in biotech require patience, with a time horizon of 10-15 years to see a drug from discovery to commercialization [13] - New Jersey offers an R&D tax credit to attract big pharma companies and has a program allowing early-stage life sciences companies to monetize their net operating losses [20][21] Company Strategy & Focus - Johnson & Johnson (J&J) has invested $50 billion in R&D and M&A since the beginning of last year [10] - J&J actively scouts the world for promising innovations and technologies to leverage its scale in research, development, manufacturing, and commercialization [6] - J&J is developing an oral medicine, icotrokinra, to treat plaque psoriasis, which is expected to be a significant breakthrough and contribute to growth in the second half of the decade [7][9]

[Music] Bringing a life-saving drug to market requires analyzing massive amounts of complex data. The pharmaceutical industry needs a faster, more automated way to extract meaning and act on it. Ivia is using Agentic AI to do exactly that.Training AI agents to navigate more than a million data streams for clinical, medical, and commercial professionals. Its healthcare grade AI platform combines a growing set of AI agents, each designed to streamline how insights turn into action. Built with NVIDIA Neotron m ...

Financial Data and Key Metrics Changes - The company has grown margins by almost 400 basis points from 2018 to now and is on track to increase its margin profile by another 300 basis points over the next four years [22][23] - The company reaffirmed a revenue growth of 5% to 7% for Q3 and expects a margin profile of approximately 14% [75][76] Business Line Data and Key Metrics Changes - The advanced facilities and advanced manufacturing sectors, which include life sciences and semiconductor industries, represent about 25% of the company's business [40] - The industrial water space is at an inflection point, with significant growth potential due to increasing water scarcity and the need for treatment systems [47] Market Data and Key Metrics Changes - The private sector continues to move forward with capital projects, particularly in life sciences and chip manufacturing, despite uncertainties like tariffs [30][31] - State and local governments have not paused projects, continuing to utilize appropriated funds [33] - The federal sector, which represents about 9% of the business, has seen some pausing but is now starting to resume projects [34][35] Company Strategy and Development Direction - The company has redefined its asset life cycle approach, engaging earlier in clients' business to optimize capital and enhance project outcomes [17][18] - The company aims to increase its global delivery model from 10% of overall delivery to potentially doubling it in the next three to five years [49][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the pipeline for the pharma sector, driven by advancements in AI for drug discovery, which allows for faster R&D processes [68][69] - The company is optimistic about the future, citing strong secular tailwinds across various markets, including water, environmental, and advanced facilities [12][13] Other Important Information - The company has a diverse project portfolio with 29,000 engagements, reducing exposure to any single client [79] - The company is focusing on enhancing its tech platforms to improve efficiency and develop unique solutions for clients [82][83] Q&A Session Summary Question: How are customers responding to the current economic environment? - Management noted that private sector clients are moving forward with capital projects, while state and local governments continue to utilize appropriated funds without pausing projects [30][33] Question: What is the company's strategy regarding the global delivery model? - The company aims to increase its global delivery model from 10% to potentially doubling it in the next three to five years, emphasizing the importance of trust built over decades with clients [49][51] Question: How does the company plan to balance M&A, buybacks, and dividends? - Management indicated that in the near term, M&A is not a focus, and the company plans to continue returning a significant portion of free cash flow to shareholders while reinvesting in itself [86]